Drugs / PM14
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05076396 | Sep 2017 → Aug 2025 | neoplastic disease or syndrome | PharmaMar | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05146440 | Nov 2021 → Nov 2025 overdue | soft tissue sarcoma | Spanish Group for Research in Sarcomas | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | PharmaMar | Results PharmaMar presents eleven scientific publications at the Annual Meeting of the American Association for Cancer Research (AACR) pharmamar.com ↗
Ecubectedin has demonstrated encouraging antitumor efficacy in both gastric and neuroendocrine-prostate cancer models. |
| 2021-09-13 | PharmaMar | Regulatory The World Health Organization grants the name ecubectedin to PharmaMar’s anti-tumor compound PM14 pharmamar.com ↗
PharmaMar (MSE:PHM) has announced today that the World Health Organization (WHO) has confirmed the International Nonproprietary Name (INN) of its investigational anti-tumor compound PM14 as ecubectedin. |
| 2015-11-03 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting ionis.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05146440 ↗ |
| Route | Intravenous | “Patients will receive PM14 as an i.v. infusion” NCT05076396 ↗ |